Search PubMed⌕ Search

Biomedical subjects

E Tsuchida

Publications and source records attributed to E Tsuchida.

At least 55 records · Page 3Linked to original sources

A use-dependent sodium channel antagonist, 619C89, in reduction of ischemic brain damage and glutamate release after acute subdural hematoma in the rat.

Acute subdural hematoma kills or disables more severely head injured patients than any other complication of cranial trauma. The main pathological factor involved is ischemic neuronal damage, which is caused by raised intracranial pressure and local effect. The authors have evaluated the hypothesis that a novel use-dependent sodium channel antagonist, 619C89, could reduce ischemic brain damage in the rat subdural hematoma model. Because previous studies have shown that focal neuronal damage may be mediated by "excitotoxic" mechanisms, and because excitatory amino acid levels have been shown to be markedly elevated after brain trauma in humans, the authors have measured levels of glutamate, aspartate, and threonine within the cortex underneath the hematoma, using in vivo microdialysis before and after induction of hematoma, in both vehicle- and drug-treated rats. Postinjury treatment with 619C89 (30 mg/kg) significantly reduced the volume of hemispheric ischemic damage produced by subdural hematoma, from 99.77 +/- 7.51 mm3 in vehicle-treated control rats to 46.07 +/- 11.06 mm3 (p = 0.0007) in drug-treated animals. In the vehicle-treated animals, induction of subdural hematoma led to a fourfold increase in glutamate in the first 30 minutes after subdural hematoma occurred. The mean extracellular glutamate concentration in these animals remained 2- to 2.6-fold increased over the following 2.5 hours. In the 619C89-treated animals, the release of glutamate from the cortex underneath the hematoma was significantly attenuated. In these rats, induction of subdural hematoma led to a 2.7-fold increase in the first 30-minute sample, but extracellular glutamate concentration returned to near-basal levels thereafter, compared with vehicle-treated animals (p < 0.05). These results show that 619C89 is highly neuroprotective in this model and that its effects may, in part, be mediated by the inhibition of glutamate release from the ischemic cortex underneath the hematoma.

Animals↗

Concurrent radiotherapy and chemotherapy with protracted continuous infusion of 5-fluorouracil in inoperable esophageal squamous cell carcinoma.

PURPOSE: The feasibility of a concurrent chemoradiotherapeutic protocol for patients with inoperable esophageal squamous cell carcinoma was tested. METHODS AND MATERIALS: Concurrent chemoradiotherapy using protracted low-dose continuous infusions of five-fluorouracil (5-FU; 250-300 mg/m2/24 h) and standard external beam irradiation was given to 28 patients with inoperable esophageal squamous cell carcinoma between November 1991 and June 1993. RESULTS: For 25 patients receiving a total dose of > or = 60 Gy and concurrent 5-FU infusion for more than 5 weeks, the complete response rate was 52%. Local progression-free rate in this chemoradiotherapy group was significantly higher than the historical controls treated by radiotherapy alone (p < 0.05). A multivariate analysis revealed the treatment scheme (concomitant chemoradiotherapy vs. radiotherapy alone) to be a significant factor in local control (p < 0.01). Swallowing pain (39%), anorexia (39%), and nausea (32%) were the most frequent early reactions. Serious late radiation complications have not been observed. CONCLUSION: The concurrent chemoradiotherapy using protracted low-dose continuous infusion of 5-FU and standard radiotherapy is an effective and safe method to obtain a local control in inoperable esophageal squamous cell carcinoma.

Aged↗

Continuous measurement of left ventricular volume in rabbit, using a two-electrode catheter.

We developed a device for monitoring instantaneous left ventricular (LV) volume using an alternating-current excitation two-electrode conductance catheter. Instantaneous conductance between a pair of electrodes was amplified by a non-inverting circuit. The level of conductance was linearly related to changes in blood volume from 0.8 to 2.0 ml in a latex balloon (r2 = 0.95), and to changes in blood volume from 0.4 to 2.2 ml in a post-mortem rabbit left ventricle (r2 = 0.99). The difference between the maximal and minimal conductance of the LV in situ during a cardiac cycle was closely correlated with changes in stroke volume, measured by an electromagnetic flow probe (r2 = 0.97). The endsystolic pressure-conductance relation (ESPCR) was highly linear (r2 = 0.92). Changes of the slope (Ees) of the ESPCR correlated directionally with changes of the time derivative of LV pressure (LVdP/dt) during intravenous infusions of dobutamine and propranolol. Accordingly, the two-electrode conductance catheter was useful in vivo in rabbits for continuously assessing changes in the LV volume.

Animals↗

The effect of the glycine site-specific N-methyl-D-aspartate antagonist ACEA1021 on ischemic brain damage caused by acute subdural hematoma in the rat.

Acute subdural hematoma (SDH) complicates about 20% of severely head-injured patients, and death and severe disability frequently result, yet over half of these patients may have been conscious, at some time after injury, implying secondary mechanisms of brain damage. Drugs that block the "excitotoxic" effects of glutamate at the N-methyl-D-aspartate (NMDA) receptor have generally been effective in reducing ischemic brain damage associated with SDH in animal models, yet these agents all appear to be associated with major behavioral side effects, in conscious patients, at neuroprotective doses. We therefore evaluated the effects of treatment with a novel antagonist for the glycine binding site of the NMDA receptor (ACEA1021) upon ischemic brain damage, in the rat SDH model. ACEA1021 may be free of psychomotor effects, and may thus permit high dose therapy in conscious trauma and stroke patients. SDH was produced by the slow injection of 0.4 mL autologous blood into the subdural space overlying the parietal cortex. brain damage was assessed histologically at 8 coronal planes, in animals sacrificed 4 h after induction of hematoma. Both pre- and posttreatment with ACEA1021 significantly reduced hemispheric ischemic damage produced by SDH. The magnitude of neuroprotection with this compound (26 to 39% reduction in infarct size) is similar to other NMDA antagonists, and the robust posttreatment effect implies that human studies with this compound should be performed in head injured patients, subject to completion of toxicology testing.

Animals↗

Synthetic hemes.

Explore the source record for details and available documents.

Binding Sites↗

Stabilized hemoglobin vesicles.

The Hb-vesicles which encapsulate the purified and concentrated Hb more than 40 g/dl with a uni- or bi-lamellar membrane are prepared by extruding the dispersion of mixed lipids through membrane filters (final pore size: 0.2 micron phi). They transport large amount of oxygen with satisfying rheological properties such as oncotic pressure and solution viscosity. Oxygen affinity of the Hb-vesicles is adjusted so as to exceed the ability of oxygen transport of human blood by coencapsulating allosteric effectors in the Hb-vesicles. The solution is sterilizable because of the diameter of Hb vesicles less than 0.2 micron phi. The Hb-vesicles are stabilized by using polyphospholipid or glycolipid as membrane components. No change in oxygen affinity and particle size was confirmed during long time storage at 4 degrees C. The stabilized Hb-vesicles can also be stored as frozen or dried state. The dried Hb-vesicles are regenerated by simply adding pure water. Simple in vitro test indicates that Hb-vesicles have the reduced inhibitory action of Hb to the EDRF-mediated vasorelaxation.

Acetylcholine↗

Acellular and cellular hemoglobin solutions as vasoconstrictive factor.

The inhibitory effects of acellular and cellular hemoglobin (Hb) solutions on endothelium-dependent vasorelaxation were investigated in rabbit thoracic aortic strips. As acellular Hb solutions, 2,3-diphosphoglycerate (DPG)-depleted Hb and pyridoxylated Hb were examined. Cellular Hb solutions included washed human fresh red cells and liposome Hb encapsulated with pyridoxal-5'-phosphate (PLP). The tissues were precontracted with phenylephrine (PE), after which acetylcholine (ACh) was added to elicit a steady-state relaxation. Acellular Hb solutions cumulatively reversed ACh-induced relaxation, and these inhibitory effects reached a plateau at 10 micrograms/ml. Increasing oxygen affinity by pyridoxylation had little effect on this. In contrast, both red cells and liposome Hb solution showed moderate inhibitory effects, and they reached a plateau at 1 mg/ml. These findings indicate that acellular Hb solutions are more potent inhibitors than cellular Hb solutions by a factor of about 100, and that the encapsulation of Hb is a preferable method to mimic the red cell.

2,3-Diphosphoglycerate↗

Convenient method to purify hemoglobin.

A convenient method to purify Hb solution from outdated RBC has been established for the starting material of Hb-based blood substitutes. To prevent MetHb formation during the procedure, Hb in RBC was carbonylated in advance. Then RBC was mixed with organic solvent for hemolysis and centrifuged for removal of stroma. The resulting SFHb solution was heated at 60 degrees C and generated precipitates were removed out by centrifugation. The purity of Hb (25 g/dl) was confirmed by SDS-PAGE. IEF and oxygen binding property of the Hb solution also guaranteed its purity and no denaturation of Hb. This method is applicable to large scale production of the purified Hb for the starting material of Hb-based blood substitutes.

Blood Substitutes↗

Structure and solution properties of lipidheme-microsphere.

Triglyceride microsphere emulsified with phospholipid derivative of heme (5,10,15,20-tetrakis[alpha,alpha,alpha,alpha-o-[2,2-dimethyl-20- [2-(trimethylammonioethoxy) phosphonatoxy]eicosanamido]phenyl]porphinatoiron(II); lipidheme) provides a totally synthetic artificial red cell (lipidheme-microsphere; LH-M). Its structure, solution properties and O2 binding ability are described. The particle diameter of the LH-M was ca. 90 nmø elucidated by electron microscopy. Viscosity of the LH-M suspension (approximately 1.5 cP) was much lower than that of human blood and the viscosity of mixed system of LH-M/human blood (1/1(v/v)) was 2.5 cP. Specific gravity, osmotic pressure, and colloid osmotic pressure of the LH-M suspension also satisfied the physiological needs. The LH-M can bind O2 reversibly in response to O2 pressure (P50(O2): 41 torr (pH 7.4, 37 degrees C)). O2 solubility of the LH-M was more than that of human blood caused by its high heme concentration.

Blood Substitutes↗

Characteristics of Hb-vesicles and encapsulation procedure.

The performance of Hb-vesicles depends on the weight ratio of Hb to lipid ([Hb]/[Lipid]). This value is improved by lowering the number of bilayer membrane of the vesicle and raising the concentration of Hb in the interior of the vesicle. Maximum [Hb]/[Lipid] ratio was obtained at ca. pH 7, that would relate to the isoelectric point (pI) of Hb at 25 degrees C. On the other hand, the [Hb]/[Lipid] ratio decreased with ionic strength and increased with lowering temperature. The Hb-vesicles encapsulating 40 g/dl Hb with only one bilayer membrane were isolated by using the difference in the density of the vesicles.

Blood Substitutes↗

Two types of totally artificial red blood cell substitutes liposome embedded heme(L/H) and lipidheme/microsphere(LHM).

Two types of totally artificial oxygen carriers were produced (1)by embedding synthetic lipidhemes (as oxygen carriers) in bilayers of liposomes as vehicles of lipidhemes (L/H) and (2)by covering clinically available fat droplets (triglyceride microspheres) with synthetic lipidhemes (LHM). Fat droplets were used as vehicles of lipidhemes. Their oxygen carrying ability in vivo was examined in beagles undergoing hemorrhagic shock. L/H delivered 15.7 to 19.2% of total oxygen delivery. From 12.7 to 24.4% of total oxygen consumption was from L/H. LHM delivered 11.6 to 7.3% of total oxygen delivery. From 13.1 to 16.4% of total oxygen consumption was from LHM. These totally synthetic red blood cell substitutes can be candidates for future clinical testing.

Animals↗

Oxygen transport and in vivo parameters of artificial red cells (ARC).

Artificial red cells (ARC) are prepared by encapsulating Hb with a polymerizable phospholipid. Their physical stability is very high and long-term preservation is possible in the frozen state. We examined the effect of blood parameters on the hematological and biochemical findings in transfused rats. The oxygen transport capacity of ARC in vivo were also tested by exchange transfusion in beagles. The oxygen binding parameters were almost the same as those of red blood cells (i.e., P50, Hill's coefficient, and oxygen transport efficiency (OTE) were 30 mmHg, 2.5, and 30%, respectively). The blood parameters after transfusion showed no significant changes when compared with the control. The oxygen transport capacity was of the same efficiency as red blood cells.

Animals↗

Lipidheme-microsphere (LH-M). A new type of totally synthetic oxygen carrier and its oxygen carrying ability.

We have succeeded in synthesizing a new type of totally artificial oxygen carrier which was produced by covering oil droplets (microsphere) with synthetic hemes (LH-M). We studied its oxygen-transporting ability in hemorrhagic dogs. Four beagles weighing about 8 kg were studied. Under controlled ventilation, exchange-transfusion of 30 ml/kg was carried out. Cardiac output, hemoglobin and LH-M concentration in the blood, and blood gas were measured to 5 hours after intravenous injection of LH-M solution. LH-M delivered 15.7 to 22.3 ml/min (11 to 16%) of oxygen to the tissue and 5.5 to 8.2 ml/min (11 to 17%) of oxygen was consumed from LH-M to 5 hours after intravenous injection. Its half-life time in the blood stream was about 12 hours. It was confirmed that LH-M transported oxygen and released it to the tissue in vivo.

Animals↗

[Recent progress and trend in the development of artificial blood].

Recent Progress and trend in the development of the blood substitutes, both of hemoglobin based substitute and totally synthetic one, are overviewed to apply them as an artificial blood. In response to the requisites as oxygen carriers, characteristics and present status are summarized for hemoglobin vesicles, modified hemoglobin (such as conjugated-, polymerized-, crosslinked-hemoglobin) including recombinant from gene-engineering, and totally synthetic oxygen carriers. Concentrated Hb encapsulated with thin phospholipid membrane (hemoglobin vesicle) transports the sufficient amount of oxygen with excellent solution properties. In vitro and in vivo data, and storability in frozen or dry states are introduced. Oxygen transporting ability in blood stream of the totally synthetic carrier (lipid-heme embedded in the bilayer of a phospholipid vesicle) is demonstrated by exchange transfusion tests in animals. Current status of their development including phase-I clinical results is also introduced as well as unsolved issues and future perspectives of the artificial blood.

Animals↗

[Progress in the red cell substitutes (artificial red cells)].

Recent progress of red cell substitutes to apply clinical use are overviewed. In response to the requisites as oxygen transporters, characteristics and present status are summarized for hemoglobin-based substitutes (polymer-conjugated Hb, polymerized Hb, crosslinked Hb). Concentrated hemoglobin covered with thin phospholipid bimolecular layer membranes (hemoglobin-vesicle) transports the sufficient amount of oxygen with excellent solution properties and safety. Furthermore, performances of two types of totally synthetic oxygen carrier are introduced such as lipid-heme embedding in the bilayer of a phospholipid vesicle and lipid-heme in the fat-microsphere composed of the emulsion for the nutrimental infusions.

Animals↗

Purification of concentrated hemoglobin using organic solvent and heat treatment.

A simple method for obtaining a purified and concentrated hemoglobin (Hb) solution (25 g/100 ml) from human red blood cells has been established. To prevent MetHb formation during the purification procedure, Hb in red blood cells was carbonylated in advance, and then washed red blood cells were mixed with organic solvents such as diethyl ether or dichloromethane for hemolysis and removal of stroma. The Hb solution was isolated by centrifugation (1900g) with the high removal efficiency of phospholipid (> 99.8%). After the solution was heated (60 degrees C, 1 h), the precipitates were removed by centrifugation. The purity of Hb was confirmed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Isoelectric focusing and oxygen-binding properties of the obtained Hb solution demonstrated its purity and showed no denaturation of globin. This purification procedure is applicable to large-scale production of the purified Hb.

Calorimetry↗